It has been anteriorly described that the expression of IL-37 is involved in the pathogenesis of atherosclerosis and that this biomarker has an inflammatory effect by reducing the expression of other inflammatory cytokines, such as interleukin-18 (IL-18) and TNF-α. This evidence concerns the gene IL18 and atherosclerosis.